[1] 武阳丰, 马冠生, 胡永华, 等. 中国居民的超重和肥胖流行现状[J]. 中华预防医学杂志, 2005, 39(5): 316-320. [2] MRAZ M, HALUZIK M.The role of adipose tissue immune cells in obesity and low-grade inflammation[J]. The Journal of Endocrinology, 2014, 222(3): R113-R127. [3] 刘丹凤. 染料木素对高脂饮食诱导的肥胖ICR小鼠脂质代谢的影响[D]. 南昌:南昌大学, 2015. [4] 王新. 木犀草素改善小鼠非酒精性脂肪肝的作用及其分子机制[D]. 合肥:合肥工业大学, 2015. [5] 禹志领, 关晓仪, 潘思源, 等. 五味子与非酒精性脂肪肝[C]//中国化学会第9届天然有机化学学术会议论文集. 长春: 东北师范大学出版社, 2012: 324. [6] 袁江兰. 表皮生长因子受体酪氨酸激酶结构域与其抑制剂染料木素的模拟对接[J]. 生物工程学报, 2008, 24(10): 1813-1817. [7] 余立华, 刘康, 刘保林. 染料木素的药理作用[J]. 药学与临床研究, 2010, 18(3): 299-302. [8] 罗芳贞. 染料木素衍生物体外抗氧化活性筛选[D]. 衡阳:南华大学, 2015. [9] 眭荣燕, 王万辉, 连磊凡, 等. 染料木素对Iso致心肌肥厚大鼠的抗氧化及抑制炎症反应作用研究[J]. 中国实验方剂学杂志, 2012, 18(19): 175-178. [10] GAN M, ZHENG T, SHEN L, et al.Genistein reverses isoproterenol-induced cardiac hypertrophy by regulating miR-451/TIMP2[J]. Biomedicine & pharmacotherapy, 2019, 112: 108618. [11] GAN M L, YANG D L, FAN Y, et al.Bidirectional regulation of genistein on the proliferation and differentiation of C2C12 myoblasts[J]. Xenobiotica, 2017, 11(1): 1-15. [12] 甘麦邻, 杨琼, 李强, 等. 染料木素的作用机制及在畜牧生产中的应用研究[J]. 现代畜牧兽医, 2018(1): 23-30. [13] 甘麦邻, 姜茹斌, 陈焱森, 等. 哺乳期母鼠饲喂染料木素对仔鼠早期生长发育的影响[J]. 四川农业大学学报, 2017, 35(1): 75-80. [14] 王遂军, 贾伟平, 包玉倩, 等. 血清脂联素与肥胖的关系[J]. 中华内分泌代谢杂志, 2005, 21(1): 36-38. [15] MUSSO G, GAMBINO R, BIROLI G, et al.Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2005, 100(11): 2438-2446. [16] 计慧. 有氧运动对非酒精性脂肪肝大鼠脂联素及肝脏TNF-α mRNA的影响[J]. 中国康复医学杂志, 2014, 29(10): 975-977. [17] 韩意, 吴立玲. 肥胖者肝脏脂联素受体mRNA水平及其与胰岛素抵抗的关系[J]. 生理科学进展2010, 41(4): 260-260. [18] GAN M L, SHEN L Y, WANG S J, et al.Genistein inhibits high-fat-induced obesity through miR-222 by targeting BTG2 and adipor1[J]. Food & Function, 2020, 2(8): 536-538. [19] 曹国钧. 血液标本不同离心时间对凝血四项实际检测值影响的研究[J]. 临床医学研究与实践, 2016, 1(16): 152-152. [20] 辛雪, 杨铮, 杨慧娣. 高脂食物诱导的肥胖小鼠不同脑区即刻早期蛋白和酪氨酸羟化酶的变化[J]. 中国应用生理学杂志, 2017, 33(6): 572-576. [21] SHEN L Y, ZHANG Y H, DU J J, et al.MicroRNA-23a regulates 3T3-L1 adipocyte differentiation[J]. Gene, 2015, 575(2P3): 761-764. [22] SALIH S M, NALLASAMY P, MUNIYANDI P, et al.Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance[J]. Journal of Diabetes, 2009, 1(4): 278-287. [23] GAO Z P, HUANG H L, WEN L.Protection effect of genistein on mice with acute liver impairment[J]. Chinese Journal of Industrial Hygiene and Occupational Diseases, 2008, 26(5): 294-295. [24] WANG W, CHEN J, MAO J, et al.Genistein ameliorates non-alcoholic fatty liver disease by targeting the thromboxane a pathway[J]. Journal of Agricultural and Food Chemistry, 2018, 66(23): 5853-5859. [25] GANAI A A, HUSAIN M.Genistein attenuates D-GalN induced liver fibrosis/chronic liver damage in rats by blocking the TGF-β/Smad signaling pathways[J]. Chemico-Biological Interactions, 2017, 261: 80-85. [26] ARUNKUMAR E, KARTHIK D, ANURADHA C V.Genistein sensitizes hepatic insulin signaling and modulates lipid regulatory genes through p70 ribosomal S6 kinase-1 inhibition in high-fat-high-fructose diet-fed mice[J]. Pharmaceutical Biology, 2013, 51(7): 815-824. [27] SAVVIDOU S, HYTIROGLOU P, ORFANOU-KOUMERKERIDOU H, et al.Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD[J]. J Clin Gastroenterol, 2009, 43(8): 765-772. [28] YAMAUCHI T, KAMON J, ITO Y, et al.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects[J]. Nature, 2003, 423(6941): 762-769. [29] BONNARD C, DURAND A, VIDAL H, et al.Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice[J]. Diabetes Metab, 2008, 34(1): 52-61. [30] FRÜHBECK G, CATALÁN V, RODRÍGUEZ A, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation[J]. Nutrients, 2019, 11(2): 454-454. [31] MARKAKI A, PSYLINAKIS E, SPYRIDAKI A.Adiponectin and end-stage renal disease[J]. Hormones (Athens, Greece), 2016, 15(3): 345-354. [32] COBBINA E, AKHLAGHI F.Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev, 2017, 49(2): 197-211. [33] ZHAO Y, XIAO X, FRANK S J, et al.Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF-α, and IL-1β[J]. Am J Physiol Endocrinol Metab, 2014, 307(2): E186-E198. [34] 郭晓鹤, 李贞娟, 张彩凤, 等. 肿瘤坏死因子-α与非酒精性脂肪肝的关系[J]. 胃肠病学和肝病学杂志, 2011, 20(7): 655-655. [35] FAN X F, DENG Y Q, Ye L, et al.Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia[J]. Chin J Integr Med, 2010, 16(2): 119-123. [36] MARTIN-RODRIGUEZ J L, GONZALEZ-CANTERO J, GONZALEZ-CANTERO A, et al. Insulin resistance and NAFLD: Relationship with intrahepatic iron and serum TNF-α using 1H MR spectroscopy and MRI[J]. Diabetes Metab, 2019, 45(5): 473-479. [37] SCHUSTER S, CABRERA D, ARRESE M, et al.Triggering and resolution of inflammation in NASH[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-364. |